Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 19/20 | 0.53 |
| ▸ | JAK2 | O60674 | 3/20 | 0.53 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | STAT1 | P42224 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25897582 | 0.88 | TYK2 (0.61) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL25897696 | 0.88 | TYK2 (0.38) | TYK2JAK2JAK1STAT3JAK3 | |
| SCHEMBL25897691 | 0.86 | TYK2 (0.45) | TYK2JAK2JAK1STAT3 | |
| SCHEMBL30703074 | 0.84 | TYK2 (0.34) | TYK2JAK2 | |
| SCHEMBL25314251 | 0.81 | TYK2 (0.54) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL25897804 | 0.79 | TYK2 (0.57) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL29810661 | 0.79 | TYK2 (0.62) | TYK2JAK2 | |
| SCHEMBL27238483 | 0.79 | TYK2 (0.62) | TYK2JAK2 | |
| SCHEMBL25318394 | 0.77 | TYK2 (0.54) | TYK2JAK2 | |
| SCHEMBL25897722 | 0.77 | TYK2 (0.61) | TYK2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4294807-A1 | TYK2 INHIBITORS AND USES THEREOF | Sudo Biosciences Limited (GB) | 2023-12-27 | — | — | EP | claimed |
| WO-2022175752-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2022-08-25 | — | — | WO | claimed |
| US-20250011335-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LIMITED (GB) | 2025-01-09 | — | — | US | disclosed |
| US-12122785-B2 | Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors | SUDO BIOSCIENCES LIMITED (GB) | 2024-10-22 | — | — | US | disclosed |
| CN-117377669-A | TYK2 inhibitor and application thereof | 苏多生物科学有限公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-4294807-A1 | TYK2 INHIBITORS AND USES THEREOF | Sudo Biosciences Limited (GB) | 2023-12-27 | — | — | EP | disclosed |
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| WO-2022175752-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2022-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12122785-B2 | Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors | TYK2, JAK1, PDXK | TYK2 1/4885JAK2 4/4885JAK1 2/4885 |
| US-20250011335-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | TYK2, PDXK, JAK1 | TYK2 1/4885JAK2 4/4885JAK1 3/4885 |
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | TYK2, PDXK, JAK1 | TYK2 1/4885JAK2 4/4885JAK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.